CIC-P 1401 - Bordeaux

Who are we?

Located at the hospital of Bordeaux, at the Bordeaux University and at the Bergonié Institute, the Plurithematic center of clinical investigation (CIC-P) 1401 of Bordeaux is a structure open to the scientific and medical community, to institutional and industrial promoters and integrates with the overall strategy of these entities.
Our missions:

• Provide a translational link between fundamental research and clinical research
• Ensure the development of institutional or industrial projects
• Bring a methodological, logistic and technic support to investigators
• Develop its own research activity
• Train to clinical research and pharmacoepidemiology
• Provide a support in the development of quality

The research activities of the CIC-P 1401 articulate around 8 axes: oncology, cardiovascular, hepato-gastroenterology, medical imaging, neuroscience, pediatric, pharmacoepidemiology and pulmonology.
To learn more: https://cic-p.u-bordeaux.fr

Example of publications in the pharmacoepidemiology axe in connection with network activities (the publications of the other axes are on the website of the CIC-P1401)

• Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N. Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation. Clin Pharmacol Ther. 2019 Jun;105(6):1439-1455.
• Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE. Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System. Drug Saf. 2019 Apr;42(4):559-572.
• Blin P, Dureau-Pournin C, Benichou J, Bonello L, Dallongeville J, Danchin N, Falissard B, Thomas-Delecourt F, Jové J, Lassalle R, Droz C, Moore N. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database. Atherosclerosis. 2019 Feb;281:98-106.
• Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N. Br Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation. J Clin Pharmacol. 2019 Feb;85(2):432-441. 
• Gouverneur A, Coutureau J, Jové J, Rouyer M, Grelaud A, Duc S, Gérard S, Smith D, Ravaud A, Droz C, Bernard MA, Lassalle R, Forrier-Réglat A, Noize P; ETNA study group and the EREBUS study group. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study. Clin Colorectal Cancer. 2019 Mar;18(1):e150-e162.
• Gouverneur A, Bezin J, Jové J, Bosco-Lévy P, Fourrier-Réglat A, Noize P. Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life. J Am Geriatr Soc. 2019 May;67(5):913-919.
• Massin P, Creuzot-Garcher C, Kodjikian L, Girmens J.-F, Delcourt C, Fajnkuchen F, Glacet-Bernard A, Guillausseau P.-J, Ponthieux A, Blin P, Grelaud A Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study. Ophthalmic Res. 2019 Mar 29:1-10.
• Bosco-Lévy P, Duret S, Picard F, Dos Santos P, Puymirat E, Gilleron V, Blin P, Chatellier G, Looten V, Moore N. Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative database. Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):194-200.
• Blin P, Samama CM, Sautet A, Benichou J, Lignot-Maleyran S, Lamarque S, Lorrain S, Lassalle R, Droz-Perroteau C, Mismetti P, Moore N. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study. Pharmacol Res. 2019 Mar;141:201-207.
• Bezin J, Moore N, Mansiaux Y, Steg PG, Pariente A. Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study. Am J Med. 2019 Jan 18. pii: S0002-9343(19)30062-2.
• Droz-Perroteau C, Blin P, Dureau-Pournin C, Thomas D, Danchin N, Tricoire J, Paillard F, Hercberg S, Guize L, Guiard E, Maïzi H, Bernard MA, Bénichou J, Moore N. Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI. Therapie. 2019 Feb 25. pii: S0040-5957(19)30032-0. 
• Guiard E, Lelievre B, Rouyer M, Zerbib F, Diquet B, Mégraud F, Tison F, Bignon E, Lassalle R, Droz-Perroteau C, Moore N, Blin P. Bismuth Concentrations In Patients Treated In Real-Life Practice With A Bismuth Subcitrate-Metronidazole-Tetracyclin Preparation. The Saphary Study. Drug Saf. 2019 May 8.
• Blin P, Dureau-Pournin C, Bénichou J, Cottin Y, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N. Comparative real-life effectiveness and safety of dabigatran or rivaroxaban versus vitamin K antagonists: a high-dimensional propensity score matched new users cohort study in the French national healthcare data system SNDS Am J Cardiovasc Drugs.2019
• Blin P, Fauchier L, Dureau-Pournin C, Sacher F, Dallongeville J, Bernard MA, Lassalle R, Droz C, Moore N. Effectiveness and safety of rivaroxaban 15 or 20 mg versus vitamin K antagonists in non-valvular atrial fibrillation. A population-based new users high-dimensional propensity score matched cohorts study. Stroke.2019

Contact Us

CIC Bordeaux CIC1401 
Bâtiment du Tondu - case 41
146 rue Léo Saignat
33076 Bordeaux cedex
05 57 57 47 37